METIS TECHBIO-P (07666) announced its interim results, with revenues of 154 million yuan, an increase of 13,399% year-on-year.

METIS TECHBIO-P (07666) released its interim results for the six months ending June 30, 2026, reporting revenue from customer contracts of RMB 154 million, a year-on-year increase of 13,399%; an adjusted net loss of RMB 51.099 million, a year-on-year decrease of 56.4%; and a loss per share of RMB 0.17. During the reporting period, the Group continued to advance the iteration of the technology platform centered around NanoForge and the conversion of research and development achievements. The AiLNP platform further improved lipid generation, property prediction, and multi-scale simulation capabilities for the entire lifecycle of LNPs, expanding its technical capabilities to actively target "invisible" lipids and LNP designs; the AiProtein platform and the antibody design agent AARON were officially launched, establishing a preliminary research and development system covering antibody generation, affinity maturation, druggability prediction, and iterative wet and dry experiments; the AiRNA platform continued to promote AI-driven RNA sequence design and optimization, completing the development and initial experimental validation of the AI-generated IRES model; the AiTEM platform also completed integration and upgrades, continually enhancing the development capabilities for insoluble drug formulations. In the field of organ and cell-specific delivery, the Group achieved stage progress in key technical directions, including in vivo screening using high-throughput DNA barcoding in non-human primates, targeted LNP site-specific coupling, myocardium-targeted LNPs, and in vivo CAR-T actively targeted LNPs. Regarding self-developed pipelines, MTS-004 is advancing preparations for NDA submission, MTS-201 has completed part B of phase I clinical trials, and clinical studies initiated by researchers such as MTS-105 and MTS-109 are progressing according to plan, with other candidates also continuing preclinical development, IIT submission, and IND preparation work. In terms of commercialization and strategic collaboration, the Group continued to promote the external value conversion of platform technology and self-developed assets during and after the reporting period. MTS-128 has completed global exclusive licensing, with the Group having received an upfront payment of $20 million and qualifying for up to $1.6 billion in milestone payments related to development, registration, and commercialization, along with tiered royalties based on product sales; the collaboration with Shide Biotechnology has advanced from the initial research and technical validation phase to the licensed development phase, with the Group having received RMB 15 million in exclusive licensing fees. At the same time, the potential total transaction amount for the NanoForge platform's OpenCGT project has exceeded RMB 6 billion, and several new research collaborations targeting liver-targeted and lung-targeted delivery systems have been established. The AiTEM platform has also entered into localized deployment cooperation with Jiangsu Hengrui Pharmaceuticals, promoting the extension of NanoForge from internal R&D empowerment to external industry applications. The Group is gradually forming a business development pattern driven by platform technology, pipeline development, and global collaboration synergy, laying the foundation for subsequent clinical development, commercialization, and international value realization.